Search results
MD Anderson Research Highlights for June 5, 2024 | Newswise
Newswise· 17 hours agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These
Cancer-fighting antibodies inject chemo directly into tumor cells, upping effectiveness
NBC NEWS· 3 days agoThe approach isn’t entirely new: The first antibody drug conjugate was approved by the Food and Drug...
What's Going On With Bio-Path Stock? - Bio-Path Hldgs (NASDAQ:BPTH)
Benzinga· 2 days agoBPTH shares are trading higher Monday after the company announced the presentation of interim...
Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
Medical Xpress· 5 days ago(ASCO) Annual Meeting. The novel anti-CD19 autologous chimeric antigen receptor (CAR) T cell therapy...
'Smart warheads' of cancer: Experts' excitement for treatment approach grows
Becker’s Hospital Review· 3 days agoCancer experts are increasingly optimistic about the potential for antibody-drug conjugates to become a standard treatment approach. The therapies involve attaching chemotherapy ...
Owasso senior’s graduation cut short due to cancer diagnosis: ‘Just complete shock’
Tulsa World· 5 days agoTate, 18, was diagnosed with acute myeloid leukemia, an aggressive blood cancer, on Tuesday, May 21...
Rgenta Therapeutics Presents Preclinical Data from Lead Program RGT-61159, a Potent Inhibitor of...
The Pilot News· 5 days ago"The data presented at ASCO 2024 demonstrate efficient and specific modulation of the oncogenic transcription factor MYB, a target that historically has been difficult to drug, by ...
Bio-Path secures $4 million in private placement By Investing.com
Investing.com· 1 day agoBio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology firm, announced today it has entered into a...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoLive from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety PR Newswire SUZHOU, China ...
ComboMATCH Precision Medicine Cancer Trials
National Cancer Institute· 1 day ago(Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice) is a group of precision medicine cancer clinical trials, including a...
